5 DNA Stocks Billionaires Are Loading Up On

In this article, we discuss 5 DNA stocks that billionaires love. If you want to read our detailed analysis of the DNA market, check out 10 DNA Stocks Billionaires Are Loading Up On. 

5. Sangamo Therapeutics, Inc. (NASDAQ:SGMO)

Number of Hedge Fund Holders: 14

Number of Billionaire Investors: 9

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) is a clinical-stage genomic medicine company that caters to serious diseases including kidney transplantation, hemophilia, sickle cell disease, and neurological disorders. On May 22, the US FDA allowed Fast Track status to be designated to Sangamo Therapeutics, Inc. (NASDAQ:SGMO)’s gene therapy, isaralgagene civaparvovec, for Fabry disease. The candidate earlier had a Orphan Drug designation and is currently in a phase 1/2 study. It is one of the best DNA stocks to watch. 

According to Insider Monkey’s first quarter database, 14 hedge funds were bullish on Sangamo Therapeutics, Inc. (NASDAQ:SGMO), and 9 of them are run by billionaire investors. Billionaire Chris Rokos’ Rokos Capital Management is the largest position holder in the company, with 6.4 million shares worth $11.4 million. 

Here is what Wasatch Ultra Growth Fund has to say about Sangamo Therapeutics, Inc. (NASDAQ:SGMO) in its Q1 2021 investor letter:

“Another weak stock in the Fund was Sangamo Therapeutics, Inc. (SGMO). Some investors may have been spooked by the resignation of Sangamo’s chief financial officer (CFO) after a tenure of less than one year. After conducting our own research, which included a conversation with the departing CFO, we believe the move was purely for personal reasons. Sangamo specializes in the treatment and cure of single-gene disorders. We remain optimistic about its future prospects, current partnerships and development pipeline— which includes gene therapy, in-vivo gene editing and ex-vivo genome medicine. (Current and future holdings are subject to risk.)”